Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rasburicase for Hyperuricemia in Pediatric NHL and AL
NCT04349306Phase 4Completed
- Sponsor
- Sanofi
- Start
- May 2020
- Primary completion
- Mar 2021
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rasburicase in hyperuricemia, sponsored by Sanofi. Primary endpoint: Incidence of Adverse Events and Serious Adverse Events. Started May 2020; status: completed.
02
Drugs
rasburicase
03
Conditions
hyperuricemia
Beyond the preview
Go deeper on NCT04349306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04349306.